直肠癌侧方盆腔淋巴结放疗加量的疗效与安全性
本研究回顾性分析2011年5月至2018年2月接受新辅助放化疗后行全直肠系膜切除术的非转移性淋巴结阳性直肠腺癌患者,比较临床阳性侧方盆腔淋巴结(LPN)加量放疗与无LPN受累患者的结局。LPN+组接受受累LPN加量至总剂量54.0–59.4 Gy,中位随访19.9个月;LPN-组中位随访30.6个月。两组3年总生存和无进展生存无差异,未观察到LPN复发,急性和慢性3级以上毒性无差异。
要点
- 临床阳性未切除LPN加量放疗未增加3级以上毒性。
- LPN+组未观察到LPN复发,3年总生存和无进展生存与LPN-组无差异。
- LPN+组样本量小、随访时间短,结论需进一步研究验证。
核心结论
- 对临床阳性、未切除的侧方盆腔淋巴结追加放疗加量是有效且毒性有限的治疗策略。
研究设计与样本
- 回顾性分析2011年5月至2018年2月接受新辅助放化疗后TME的非转移性淋巴结阳性直肠腺癌患者。
- LPN-组41例接受45 Gy/25次后原发肿瘤和区域引流淋巴结加量5.4 Gy/3次。
- LPN+组12例对受累LPN追加加量至总剂量54.0–59.4 Gy。
- 比较两组局部区域控制、总生存、无进展生存和治疗相关毒性。
主要发现
- LPN-组中位随访30.6个月,LPN+组中位随访19.9个月。
- 未观察到LPN复发,急性和慢性3级以上毒性无差异。
关键数值与推荐
- LPN-组放疗剂量45 Gy/25次,原发肿瘤和区域引流淋巴结加量5.4 Gy/3次。
- LPN+组受累LPN加量至总剂量54.0–59.4 Gy。
临床怎么用
- 对临床阳性且TME不会切除的LPN可考虑追加放疗加量至54.0–59.4 Gy。
- 治疗决策需结合LPN状态和多学科评估,关注急性和慢性毒性。
局限性
- 回顾性研究,LPN+组样本量小(12例)且随访时间较短(中位19.9个月)。
- LPN转移的负向预后影响已知,但本研究样本不足以得出确定性结论。
- 需要更多研究优化该患者亚组的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In rectal cancer, the presence of extramesorectal/lateral pelvic lymph node (LPN) is associated with higher risk of locoregional and distant recurrences. LPNs are not typically resected during a standard total mesorectal excision (TME) procedure, and the optimal management for these patients is controversial. We assessed the safety and efficacy of adding a radiation therapy boost to clinically positive LPN during neoadjuvant chemoradiation therapy for rectal cancer. METHODS AND MATERIALS: We analyzed nonmetastatic, lymph node positive rectal adenocarcinoma patients treated with neoadjuvant chemoradiation therapy followed by TME between May 2011 and February 2018. Patients without LPN involvement received external beam radiation therapy (45 Gy in 25 fractions) to the primary tumor and regional draining lymph node basins followed by a boost (5.4 Gy in 3 fractions) to gross disease. Patients with clinically positive LPN that would not be removed during TME received an additional boost (up to a total dose between 54.0 and 59.4 Gy) to the involved LPNs. We compared locoregional control, overall survival, progression-free survival, and treatment-related toxicity between these 2 groups. RESULTS: Fifty-three patients were included in this analysis with median follow-up of 30.6 months for the LPN- group (n = 41) and 19.9 months for the LPN+ group (n = 12). There was no difference in 3-year overall survival (90.04% vs 83.33%, P = .890) and progression-free survival (80.12% vs 80.21%, P = .529) between the 2 groups. We did not observe any LPN recurrences. There were no differences in rates of acute grade 3+ or chronic toxicities. CONCLUSIONS: Despite the well-documented negative prognostic effect of LPN metastasis, we observed promising outcomes for LPN+ patients treated with an additional radiation boost. Our results suggest that radiation therapy boost to clinically involved, unresected LPN is an effective treatment approach with limited toxicity. Additional studies are needed to optimize treatment strategies for this unique patient subset.
引用
- Chen H, Nguyen KNB, Huang H, et al. Effect and Safety of Radiation Therapy Boost to Extramesorectal Lymph Nodes in Rectal Cancer. Pract Radiat Oncol. 2019. PMID: 31866577. doi:10.1016/j.prro.2019.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。